Effect of the Traditional Chinese Medicine Shuganjieyu Formula on Constipation Type Irritable Bowel Syndrome and Brain-gut Axis in Rats

doi:10.12300/j.issn.1674-5817.2022.135

Abstract

Abstract:

Objective To observe the intervention effect of Shuganjieyu Formula on the rat model of constipation irritable bowel syndrome (IBS-C) and its effects on 5- hydroxytryptamine (5-HT), corticotropin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH), and to explore their mechanism of regulating brain-gut axis function. Methods Totally fourty rats were randomly divided into four groups with 10 rats in each group, including normal control group, model group, low (5 mg/kg) and high (20 mg/kg) doses of Shuganjieyu Formula groups. Except for the normal control group, the other three groups of rats were gavaged with ice water for preparing the IBS-C model. Subsequently, the low and high doses groups of rats were treated with Shuganjieyu Formula for 2 weeks via oral gavage. The body weight of rats, total particle number and water content of fecal in the four groups were observed for 28 days. At last, serum of inferior vena cava and colon were collected from rats after anesthesia of 3% pentobarbital sodium. The morphological changes of colon tissue and the count of mast cells (MC) were observed with light microscope. Immunohistochemistry was used to detect the positive expression of 5-HT in the colon of rats in each group. The serum levels of 5-HT, CRH and ACTH were detected by ELISA. Results Compared with the normal control group, the body weight of rats in IBS-C model group increased slowly, the number of fecal grains and the fecal water content decreased (P<0.05); the number of MC cells, the positive expression of 5-HT in colon tissue increased significantly in IBS-C group (P<0.05); the content of 5-HT in serum increased significantly, while the content of ACTH decreased significantly in IBS-C group (P<0.05). Colonic morphology showed no abnormal pathological changes in IBS-C model group. Compared with the model group, the body weight, fecal granule number and fecal water content of rats in each dose group of traditional Chinese medicine increased, but the differences were not statistically significant. The colon tissue structure of rats in each dose group of traditional Chinese medicine was normal. Compared with the model group, the number of MC cells and the positive expression of 5-HT in each dose group of traditional Chinese medicine decreased significantly (P<0.05), the content of 5-HT in serum decreased significantly, while the content of ACTH increased significantly (P<0.05). The dose-effect relationship between the low and high doses groups of Shuganjieyu Formula was not statistically significant. Conclusion The traditional Chinese medicine Shuganjieyu Formula can effectively improve the dysfunction of brain-gut axis in IBS-C model rats, and has a good therapeutic effect on IBS-C.

Key words: Constipation irritable bowel syndrome, Shuganjieyu Formula, Brain-gut axis function, Rats

CLC Number:

R-332

Bin WU,Xu WANG,Dongxu FU,et al. Effect of the Traditional Chinese Medicine Shuganjieyu Formula on Constipation Type Irritable Bowel Syndrome and Brain-gut Axis in Rats[J]. Laboratory Animal and Comparative Medicine, 2022, 42(6): 551-559. DOI: 10.12300/j.issn.1674-5817.2022.135.

Figures/Tables 4

Figure 1 Change trend of body mass, fecal particles and fecal water content of rats in each groupNote： NC, normal control group; Model, model control group; Low-dose, Shuganjieyu Formula low-dose group (5 g/kg); High-dose, Shuganjieyu Formula high-dose group (20 g/kg). A: Changes in body mass of rats with time, compared to the model group, *P<0.05, n=10; B and C: Tendency of changes in daily feces and their water content in all groups of rats, compared to the normal control group, *P<0.05, n=10.

Figure 2 Histopathological changes (toloniumchloride，×200) and the number of mast cells in colon of ratsNote：Left, the results of modified toloniumchloride staining of colon tissue (the scale of each small figure was all 50 μm). A: Normal control group; B: Model control group; C and D: Low- (5 g/kg) and high- (20 g/kg) dose of Shuganjieyu Formula groups. E: The statistical data of mass cells positive cells, compared to the model group, **P<0.01，***P<0.001, n=10。

Figure 3 5-HT immunohistochemical staining of colon tissue of rats （DAB，×200 ）Note：On the left is the colon tissue immunohistochemical staining (DAB, all of which have the same scale size, 50 μm). A is the normal control group (NC), B is the model control group (Model), C is the low-dose (5 g/kg) group of Shuganjieyu Formula (low-dose), D is the high-dose (20 g/kg) group of Shuganjieyu Formula (high-dose). E: The semi-quantitative statistical graph of 5-hydroxytryptamine (5-HT) positive expression area, compared with the model group, **P<0.01, n=10。

Figure 4 Comparison of 5-HT, CRH and ACTH contents in serum of rats in the four groups (ELISA)Note: ACTH, adrenocorticotropic hormone; CRH, corticotropin releasing hormone; 5-HT, 5-hydroxytryptamine. NC, Normal control group; Model, model control group; Low-dose, Shuganjieyu Formula low-dose group (5 g/kg); High-dose, Shuganjieyu Formula high-dose group (20 g/kg). Compared to the model group，ns indicates P>0.05，*P<0.05，**P<0.01，***P<0.001; n=10.

References 25

1	刘建湘, 刘新光. 肠易激综合征的诊断与治疗[J]. 中国实用内科杂志, 2008, 28(7):524-526. DOI:10.3969/j.issn.1005-2194.2008.07.006 .
	LIU J X, LIU X G. Diagnosis and treatment of irritable bowel syndrome[J]. Chin J Pract Intern Med, 2008, 28(7):524-526. DOI:10.3969/j.issn.1005-2194.2008.07.006 .
2	MERTZ H R. Irritable bowel syndrome[J]. N Engl J Med, 2003, 349(22):2136-2146. DOI:10.1056/nejmra035579 .
3	中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 中国肠易激综合征专家共识意见(2015年, 上海)[J]. 中华消化杂志, 2016, 36(5):299-312. DOI:10.3760/cma.j.issn.0254-1432.2016.05.005 .
	Gastrointestinal Functional Diseases Collaborative Group of Digestive Branch of Chinese Medical Association, Gastro-intestinal Dynamics Group of Digestive Branch of Chinese Medical Association. Expert consensus on irritable bowel syndrome in China (Shanghai, 2015) [J]. Chin J Dig, 2016(5):299-312. DOI: 10.3760/cma. j.issn. 0254-1432.2016.05.005 .
4	宋怡然, 梁笑楠, 李忱阳, 等. «2020年中国肠易激综合征专家共识意见»解读[J]. 临床荟萃, 2021, 36(7): 628-631.
	SONG Y R, LIANG X N, LI C Y, et al. Interpretation on Chinese expert consensus of irritable bowel syndrome in 2020[J]. Clin Focus, 2021, 36(7): 628-631.
5	LEE C, DOO E, CHOI J M, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and Meta-analysis[J]. J Neurogastroenterol Motil, 2017, 23(3):349-362. DOI:10.5056/jnm16220 .
6	ZHANG Q E, WANG F, QIN G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies[J]. Int J Biol Sci, 2018, 14(11):1504-1512. DOI:10.7150/ijbs.25001 .
7	ZAMANI M, ALIZADEH-TABARI S, ZAMANI V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2019, 50(2):132-143. DOI:10.1111/apt.15325 .
8	HU Z C, LI M X, YAO L, et al. The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis[J]. BMC Gastroenterol, 2021, 21(1):23. DOI:10.1186/s12876-020-01593-5 .
9	吴斌, 朱宇均, 黄金路. 从"气"论治法对便秘型肠易激综合征的临床疗效及对部分脑肠肽的影响[J]. 中国医药科学, 2022, 12(11):9-13, 26.
	WU B, ZHU Y J, HUANG J L. Clinical efficacy of the Qi in treating constipation-predominant irritable bowel syndrome and its effect on brain-gut peptides[J]. China Med Pharm, 2022, 12(11):9-13, 26.
10	彭丽华, 杨云生, 孙刚, 等. 便秘型肠易激综合征新概念模型的建立[J]. 世界华人消化杂志, 2004, 12(1): 112-116.
	PENG L H, YANG Y S, SUN G, et al. A new model of constipation-predominant irritable bowel syndrome in rats[J]. World Chin J Dig, 2004, 12(1): 112-116.
11	QUIGLEY E M M. Microbiota-brain-gut axis and neuro-degenerative diseases[J]. Curr Neurol Neurosci Rep, 2017, 17(12):94. DOI:10.1007/s11910-017-0802-6 .
12	SPIELMAN L J, GIBSON D L, KLEGERIS A. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases[J]. Neurochem Int, 2018, 120:149-163. DOI:10.1016/j.neuint.2018.08.005 .
13	VERMEULEN W, DE MAN J G, PELCKMANS P A, et al. Neuroanatomy of lower gastrointestinal pain disorders[J]. World J Gastroenterol, 2014, 20(4):1005-1020. DOI:10.3748/wjg.v20.i4.1005 .
14	CHRISTIANSON J A, BIELEFELDT K, ALTIER C, et al. Development, plasticity and modulation of visceral afferents[J]. Brain Res Rev, 2009, 60(1):171-186. DOI:10.1016/j.brainresrev.2008.12.004 .
15	GONDA X, PETSCHNER P, ESZLARI N, et al. Effects of different stressors are modulated by different neuro-biological systems: the role of GABA-a versus CB1 receptor gene variants in anxiety and depression[J]. Front Cell Neurosci, 2019, 13: 138. DOI:10.3389/fncel.2019.00138 .
16	HOUTEPEN L C, SCHÜR R R, WIJNEN J P, et al. Acute stress effects on GABA and glutamate levels in the prefrontal cortex: A 7T ¹H magnetic resonance spectroscopy study[J]. Neuroimage Clin, 2017, 14:195-200. DOI:10.1016/j.nicl.2017. 01.001 .
17	LIBERZON I, KRSTOV M, YOUNG E A. Stress-restress: effects on ACTH and fast feedback[J]. Psychoneuroendocrinology, 1997, 22(6):443-453. DOI:10.1016/s0306-4530(97)00044-9 .
18	SANTOS J, ALONSO C, VICARIO M, et al. Neuro-pharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome[J]. Curr Mol Med, 2008, 8(4):258-273. DOI:10.2174/156652408784533788 .
19	ROBLES A, PEREZ INGLES D, MYNEEDU K, et al. Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: a systematic review and meta-analysis[J]. Neurogastroenterol Motil, 2019, 31(12): e13718. DOI:10.1111/nmo.13718 .
20	YU Y C, LI J, ZHANG M X, et al. Resveratrol improves brain-gut axis by regulation of 5-HT-dependent signaling in the rat model of irritable bowel syndrome[J]. Front Cell Neurosci, 2019, 13:30. DOI:10.3389/fncel.2019.00030 .
21	刘欢, 张孟历, 于猛, 等. 醋制香附挥发油抗抑郁活性及化学成分分析[J]. 药物评价研究, 2020, 43(3):436-442. DOI:10.7501/j.issn.1674-6376.2020.03.012 .
	LIU H, ZHANG M L, YU M, et al. Antidepressant activity evaluation and GC-MS analysis of volatile oil from vinegar-made Cyperi rhizome[J]. Drug Eval Res, 2020, 43(3):436-442. DOI:10.7501/j.issn.1674-6376.2020.03.012 .
22	宋美卿, 仝立国, 贾力莉, 等. 疏肝行气对药"香橼-佛手"对抑郁大鼠行为学及海马单胺类神经递质的影响[J]. 中国药物与临床, 2021, 21(5):737-740. DOI:10.11655/zgywylc2021.05.006 .
	SONG M Q, TONG L G, JIA L L, et al. Effects of Shuxingqi medicine "Citron-bergamot" on behavior and monoamine neurotransmitters in hippocampus of depressed rats[J]. Chin Remedies Clin, 2021, 21(5):737-740. DOI:10.11655/zgywylc2021.05.006 .
23	方圆之, 高杰. 白芍的通便作用及其对便秘小鼠结肠AQP4、VIP表达的影响[J]. 山东中医杂志, 2017, 36(1):62-65. DOI:10.16295/j.cnki.0257-358x.2017.01.022 .
	FANG Y Z, GAO J. Cathartic effect of Baishao and its effect on AQP4 and VIP in mice with constipation[J]. Shandong J Tradit Chin Med, 2017, 36(1):62-65. DOI:10.16295/j.cnki.0257-358x.2017.01.022 .
24	FAN R, HUANG X, WANG Y, et al. Ethnopharmacokinetic- and activity-guided isolation of a new antidepressive compound from fructus aurantii found in the traditional Chinese medicine Chaihu-Shugan-San: a new approach and its application[J]. Evid Based Complement Alternat Med, 2012, 2012:607584. DOI:10.1155/2012/607584 .
25	李陈雪, 杨玉赫, 冷德生, 等. 枳壳化学成分及药理作用研究进展[J]. 辽宁中医药大学学报, 2019, 21(2):158-161. DOI:10.13194/j.issn.1673-842x.2019.02.043 .
	LI C X, YANG Y H, LENG D S, et al. Research progress on chemical constituents and quality evaluation of fructus aurantii[J]. J Liaoning Univ Tradit Chin Med, 2019, 21(2):158-161. DOI:10.13194/j.issn.1673-842x.2019.02.043 .

[1]	QIN Chao, LI Shuangxing, ZHAO Tingting, JIANG Chenchen, ZHAO Jing, YANG Yanwei, LIN Zhi, WANG Sanlong, WEN Hairuo. Study on the 90-day Feeding Experimental Background Data of SD Rats for Drug Safety Evaluation [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 439-448.
[2]	LIU Liyu, JI Bo, LIU Xiaoxuan, FANG Yang, ZHANG Ling, GUO Tingting, QUAN Ye, LI Hewen, LIU Yitian. Exploration of Rat Fetal Lung Tissue Fixation Methods [J]. Laboratory Animal and Comparative Medicine, 2025, 45(4): 432-438.
[3]	PAN Yicong, JIANG Wenhong, HU Ming, QIN Xiao. Optimization of Surgical Procedure and Efficacy Evaluation of Aortic Calcification Model in Rats with Chronic Kidney Disease [J]. Laboratory Animal and Comparative Medicine, 2025, 45(3): 279-289.
[4]	LIU Zhiwei, YANG Ran, LIAN Hao, ZHANG Yu, JIN Lilun. Cartilage Protection and Anti-Inflammatory Effects of Fraxetin on Monosodium Iodoacetate-Induced Rat Model of Osteoarthritis [J]. Laboratory Animal and Comparative Medicine, 2025, 45(3): 259-268.
[5]	JIANG Meng, HAO Shulan, TONG Liguo, ZHONG Qiming, GAO Zhenfei, WANG Yonghui, WANG Xixing, JI Haijie. Dynamic Evaluation of Vinorelbine-Induced Phlebitis of Dorsalis Pedis Vein in a Rat Model [J]. Laboratory Animal and Comparative Medicine, 2025, 45(3): 251-258.
[6]	LIAN Hui, JIANG Yanling, LIU Jia, ZHANG Yuli, XIE Wei, XUE Xiaoou, LI Jian. Construction and Evaluation of a Rat Model of Abnormal Uterine Bleeding [J]. Laboratory Animal and Comparative Medicine, 2025, 45(2): 130-146.
[7]	YIN Yulian, MA Lina, TU Siyuan, CHEN Ling, YE Meina, CHEN Hongfeng. Establishment and Evaluation of a Rat Model of Non-Puerperal Mastitis [J]. Laboratory Animal and Comparative Medicine, 2024, 44(6): 587-596.
[8]	YANG Jin, YU Shiya, LIN Nan, FANG Yongchao, ZHAO Hu, QIU Jinwei, LIN Hongming, CHEN Huiyan, WANG Yu, WU Weihang. Effect of Modified Duodenal Exclusion Surgery on Glucose Metabolism in Rats with Type 2 Diabetes Mellitus [J]. Laboratory Animal and Comparative Medicine, 2024, 44(5): 523-530.
[9]	QI Longju, CHEN Shiyuan, LIAO Zehua, SHI Yuanhu, SUN Yuyu, WANG Qinghua. Transcriptomic Analysis of Menstrual Blood-Derived Stem Cells Transplantation Combined with Exercise Training in Promoting Spinal Cord Injury Recovery in Rats [J]. Laboratory Animal and Comparative Medicine, 2024, 44(5): 531-542.
[10]	ZHANG Naiqun, YUAN Piaopiao, CAO Linrong, YING Na, YANG Taotao. Application of PNR Detection in the Diagnosis and Drug-efficacy Evaluation of Diabetic Kidney Disease in Rats [J]. Laboratory Animal and Comparative Medicine, 2024, 44(5): 543-549.
[11]	ZHENG Yiqing, DENG Yasheng, FAN Yanping, LIANG Tianwei, HUANG Hui, LIU Yonghui, NI Zhaobing, LIN Jiang. Application Analysis of Animal Models for Pelvic Inflammatory Disease Based on Data Mining [J]. Laboratory Animal and Comparative Medicine, 2024, 44(4): 405-418.
[12]	XIAO Pan, WANG Hongyi, LU Lu, ZHANG Mei, CHEN Keming, SHEN Dongshuai, NIU Tingxian. Screening of Hypoxia-Sensitive and Hypoxia-Tolerant Wistar Rats and Preliminary Exploration of Hypoxia Sensitivity in Their G₁Generation [J]. Laboratory Animal and Comparative Medicine, 2024, 44(4): 374-383.
[13]	Xiaoyu ZHU, Hantao YUAN, Sibo LI. MicroRNA-887-3p Inhibited MDM4 Expression and Proliferation but Promoted Apoptosis of Intervertebral Disc Annulus Fibrosus Cells in Rats [J]. Laboratory Animal and Comparative Medicine, 2024, 44(3): 270-278.
[14]	Jinhua HU, Jingjie HAN, Min JIN, Bin HU, Yuefen LOU. Effects of Puerarin on Bone Density in Rats and Mice: A Meta-analysis [J]. Laboratory Animal and Comparative Medicine, 2024, 44(2): 149-161.
[15]	Liya ZHAO, Liju NI, Caiqin ZHANG, Jianping TANG, Yangzheng YAO, Yanyan NIE, Xiaoxue GU, Ying ZHAO. Establishing a Genetic Detection Protocol of Single Nucleotide Polymorphisms Panels in Inbred Rats Based on Multiplex PCR-LDR [J]. Laboratory Animal and Comparative Medicine, 2023, 43(5): 548-558.